|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Gray-Schopfer V, Wellbrock C and Marais R:
Melanoma biology and new targeted therapy. Nature. 445:851–857.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miller AJ and Mihm MC Jr: Melanoma. N Engl
J Med. 355:51–65. 2006. View Article : Google Scholar
|
|
4
|
Korn EL, Liu PY, Lee SJ, et al:
Meta-analysis of phase II cooperative group trials in metastatic
stage IV melanoma to determine progression-free and overall
survival benchmarks for future phase II trials. J Clin Oncol.
26:527–534. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He GX, Pei G, Zhou TD and Zhou XX:
Determination of total flavonoids and dihydromyricetin in
Ampelopsis grossedentala(Hand-Mazz) (W.T. Wang). Zhongguo
Zhong Yao Za Zhi. 25:423–425. 2000.(In Chinese).
|
|
6
|
Du Q, Cai W, Xia M and Ito Y: Purification
of (+)-dihydromyricetin from leaves extract of Ampelopsis
grossedentata using high-speed countercurrent chromatograph
with scale-up triple columns. J Chromatogr A. 973:217–220.
2002.
|
|
7
|
Wang Y, Zhou L, Li R and Wang Y:
Determination of ampelopsin in the different parts of Ampelopsis
grossedentata in different seasons by RP-HPLC. Zhong Yao Cai.
25:23–24. 2002.(In Chinese).
|
|
8
|
Murakami T, Miyakoshi M, Araho D, et al:
Hepatoprotective activity of tocha, the stems and leaves of
Ampelopsis grossedentata, and ampelopsin. Biofactors.
21:175–178. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shen Y, Lindemeyer AK, Gonzalez C, Shao
XM, Spigelman I, OIsen RW and Liang J: Dihydromyricetin as a novel
anti-alcohol intoxication medication. J Neurosci. 32:390–401. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang YS, Ning ZX, Yang SZ and Wu H:
Antioxidation properties and mechanism of action of
dihydromyricetin from Ampelopsis grossedentata. Yao Xue Xue
Bao. 38:241–244. 2003.PubMed/NCBI
|
|
11
|
He G, Du F, Yang W, Pei G and Zhu Y:
Effects of tengcha flavonoids on scavenging oxygen free radicals
and inhibiting lipid-peroxidation. Zhong Yao Cai. 26:338–340.
2003.(In Chinese).
|
|
12
|
Zhong ZX, Qin JP, Zhou GF and Chen XF:
Experimental studies of hypoglycemic action on total flavone of
Ampelopsis grossedentata from Guangxi. Zhongguo Zhong Yao Za
Zhi. 27:687–689. 2002.(In Chinese).
|
|
13
|
Qi S, Xin Y, Guo Y, Diao Y, Kou X, Luo L
and Yin Z: Ampelopsin reduces endotoxic inflammation via repressing
ROS-mediated activation of PI3K/Akt/NF-κB signaling pathways. Int
Immunopharmacol. 12:278–287. 2012.PubMed/NCBI
|
|
14
|
Ni F, Gong Y, Li L, Abdolmaleky HM and
Zhou JR: Flavonoid Ampelopsin inhibits the growth and metastasis of
prostate cancer in vitro and in mice. PloS One. 7:e388022012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang B, Dong S, Cen X, et al: Ampelopsin
sodium exhibits antitumor effects against bladder carcinoma in
orthotopic xenograft models. Anticancer Drugs. 23:590–596. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zeng S, Liu D, Ye Y, Wang L and Wang W:
Anti-tumor effects of ampelopsin on human lung cancer GLC-82
implanted in nude mice. Zhong Yao Cai. 27:842–845. 2004.(In
Chinese).
|
|
17
|
Gao Q, Yang X and Ou M: Effect of serum
containing tengcha total flavonoid and dihydromyricetin on
proliferation and apoptosis of HepG2 cells. Zhongguo Zhong Yao Za
Zhi. 36:500–503. 2011.(In Chinese).
|
|
18
|
Luo GQ, Zeng S and Liu DY: Inhibitory
effects of ampelopsin on angiogenesis. Zhong Yao Cai. 29:146–150.
2006.(In Chinese).
|
|
19
|
Liu D and Luo M: Study on inhibitory
effect of ampelopsin on melanoma by serologic pharmacological
method. Zhong Yao Cai. 24:348–350. 2001.(In Chinese).
|
|
20
|
Zheng HQ and Liu DY: Anti-invasive and
anti-metastatic effect of ampelopsin on melanoma. Ai Zheng.
22:363–367. 2003.(In Chinese).
|
|
21
|
Liu DY, Zheng HQ and Luo GQ: Effects of
ampelopsin on invasion and metastasis of B16 mouse melanoma in vivo
and in vitro. Zhongguo Zhong Yao Za Zhi. 28:957–961. 2003.(In
Chinese).
|
|
22
|
Massaoka MH, Matsuo AL, Figueiredo CR, et
al: Jacaranone induces apoptosis in melanoma cells via ROS-mediated
downregulation of Akt and p38 MAPK Activation and displays
antitumor activity in vivo. PLoS One. 7:e386982012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Crighton D, Wilkinson S, O’Prey J, et al:
DRAM, a p53-induced modulator of autophagy, is critical for
apoptosis. Cell. 126:121–134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ferlay J, Parkin DM and
Steliarova-Founcher E: Estimates of cancer incidence and mortatlity
in Europe in 2008. Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sondak VK, Sabel MS and Mulé JJ:
Allogeneic and autologous melanoma vaccines: where have we been and
where are we going? Clin Cancer Res. 12:2337s–2341s. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garbe C, Peris K, Hauschild A, et al:
Diagnosis and treatment of melanoma: European Consensus-based
interdisciplinary guideline. Eur J Cancer. 46:270–283. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kruse JP and Gu W: Modes of p53
regulation. Cell. 137:609–622. 2009. View Article : Google Scholar
|
|
28
|
Tang Y, Luo J, Zhang W and Gu W:
Tip60-dependent acetylation of p53 modulates the decision between
cell-cycle arrest and apoptosis. Mol Cell. 24:827–839. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sykes SM, Mellert HS, Holbert MA, Li K,
Marmorstein R, Lane WS and McMahon SB: Acetylation of the p53
DNA-binding domain regulates apoptosis induction. Mol Cell.
24:841–851. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Armstrong MJ, Stang MT, Liu Y, et al:
Interferon regulatory factor 1 (IRF-1) induces
p21WAF1/CIP1 dependent cell cycle arrest and
p21WAF1/CIP1 independent modulation of suivivin in
cancer cells. Cancer Lett. 319:56–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tu Ys, Kang XL, Zhou JG, Lv XF, Tang YB
and Guan YY: Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in
simvastatin induced S-phase cell cycle arrest and apoptosis in
multiple myeloma cells. Eur J Pharmacol. 670:356–364. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bonnefont J, Laforge T, Plastre O, Beck B,
Sorce S, Dehay C and Krause KH: Primate-specific RFPL1 gene
controls cell-cycle progression through cyclin B1/Cdc2 degradation.
Cell Death Differ. 18:293–303. 2011.
|
|
33
|
Watanabe G, Behrns KE, Kim JS and Kim RD:
Heat shock protein 90 inhibition abrogates hepatocellular cancer
growth through cdc2-mediated G2/M cell cycle arrest and
apoptosis. Cancer Chemother Pharmacol. 64:433–443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yonish-Rouach E, Resnitzky D, Lotem J,
Sachs L, Kimchi A and Oren M: Wild-type p53 induces apoptosis of
myeloid leukaemic cells that is inhibited by interleukin-6. Nature.
352:345–357. 1991. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Donauer J, Schreck I, Liebel U and Weiss
C: Role and interaction of p53, BAX and the stress-activated
protein kinases p38 and JNK in benzo(a)pyrene-diolepoxide induced
apoptosis in human colon carcinoma cells. Arch Toxical. 86:329–337.
2012. View Article : Google Scholar
|
|
36
|
Tomita Y, Marchenko N, Erster S, et al: WT
p53, but not tumor-derived mutants, bind to Bcl2 via the DNA
binding domain and induce mitochondrial permeabilization. J Biol
Chem. 281:8600–8606. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qin JZ, Ziffra J, Stennett L, Bodner B,
Bonish BK, Chaturvedi V, et al: Proteasome inhibitors trigger
NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res.
65:6282–6293. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Escárcega RO, Fuentes-Alexandro S,
Garcı́a-Carrasco M, Gatica A and Zamora A: The transcription factor
nuclear factor-kappa B and cancer. Clin Oncol. 19:154–161.
2007.
|
|
39
|
Uchida S, Yoshioka K, Kizu R, et al:
Stress-activated mitogen-activated protein kinase c-Jun
NH2-terminal kinase and p38 target Cdc25B for degradation. Cancer
Res. 69:6438–6444. 2009. View Article : Google Scholar : PubMed/NCBI
|
